1.Expression characteristics, targeted regulation, and synergistic mechanisms of IGF2BP3 and UXS1 in hepatocellular carcinoma
DENG Yulong ; WEI Lianqing ; WU Xingchen ; XIE Xiaoting ; XIONG Dandan
Chinese Journal of Cancer Biotherapy 2026;33(1):66-76
[摘 要] 目的:探讨胰岛素样生长因子2 mRNA结合蛋白3(IGF2BP3)、尿苷二磷酸-葡萄糖醛酸脱羧酶1(UXS1)在肝细胞癌(HCC)中的表达特征、预后价值及两者协同作用的分子机制。方法:整合UALCAN、cBioPortal、ENCORI、TISCH2、GDSC等公共数据库的转录组数据,对IGF2BP3和UXS1进行表达、预后评估、功能富集及药物敏感性等分析。收集GEO数据库的单细胞RNA测序(scRNA-seq)数据,分析细胞通信、单细胞代谢评分,系统解析IGF2BP3-UXS1轴在HCC中的具体作用。结果:IGF2BP3、UXS1在HCC组织中均显著高表达,且高表达患者总生存期显著缩短(均P < 0.05)。采用CRISPP技术敲除IGF2BP3或UXS1后,多种HCC细胞的增殖能力受到明显抑制。scRNA-seq分析揭示了IGF2BP3、UXS1在肝细胞等细胞类型中的广泛表达分布,前者在细胞分化晚期上调,后者则在细胞分化早、中期高表达。IGF2BP3、UXS1高表达组均显著激活了MIF通路,同时IGF2BP3的高表达削弱了成纤维细胞的相互作用,而UXS1的高表达则增强了T细胞的信号转导功能。IGF2BP3与UXS1在表达相关性中存在显著的正相关(r = 0.432,P < 0.05)。沉默IGF2BP3结合位点会导致UXS1表达水平变化(F = 0.333)。功能富集分析提示,IGF2BP3与UXS1协同调控能量代谢、蛋白质翻译等生物学过程。在IGF2BP3或UXS1高表达的细胞亚群中,发现两者与多个糖代谢相关通路存在显著关联。IGF2BP3、UXS1高表达的患者对优普色替等药物表现出显著的敏感性,还对药物那维托克等表现出显著的耐药性。结论: IGF2BP3、UXS1在HCC中高表达,两者通过调控糖代谢重编程的协同作用促进HCC恶性生物学行为。
2.Pre-operative risk assessment of hepatocellular carcinoma recurrence in liver transplant recipients by non-invasive detection of pre-existing genetic lesions
Suqin YANG ; Sunbin LING ; Jianhua LI ; Yan WANG ; Jiapei WANG ; Qiwei HUANG ; Fanming LIU ; Yiqi ZHUANG ; Yingyu ZHENG ; Rui WANG ; Zhe YANG ; Xiaoping ZHENG ; Kai WANG ; Zhikun LIU ; Jun CHEN ; Jianguo WANG ; Haiyang XIE ; Lin ZHOU ; Leiming CHEN ; Guoqiang CAO ; Dandan CHEN ; Junfang JI ; Bin ZHAO ; Chao JIANG ; Di LU ; Xuyong WEI ; Hangjin JIANG ; Qiaonan SHAN ; Hengbo SHI ; Yong-Zhen XU ; Shusen ZHENG ; Zhengxin WANG ; Shengda LIN ; Xiao XU
Clinical and Molecular Hepatology 2026;32(2):884-903
Background/Aims:
Liver transplantation (LT) following total hepatectomy is a life-saving treatment for hepatocellular carcinoma (HCC). The HCC recurrence after LT hinders the effectiveness of the procedure. The objective of this study is to develop a pre-operative risk stratification model based on a liquid biopsy.
Methods:
We conducted a comprehensive multi-omics study of 260 HCC patients from three centers, including clinical data, low-coverage whole-genome sequencing of cell-free DNA (cfDNA) from plasma, as well as whole-exome, single-nucleus RNA, and spatial transcriptomics from matched tumor and non-tumor tissues.
Results:
We identified cfDNA-derived copy number alteration (CNA) signatures associated with post-transplant recurrence. By integrating cfDNA-derived CNA profiles with single-cell transcriptomic data, we traced recurrence-associated cfDNA to a distinct subpopulation of malignant cells within the primary tumor. These cells were embedded in a pro-metastatic microenvironment of specialized endothelial subtypes and cancer-associated fibroblasts. Notably, most recurrence-associated lesions were detectable in cfDNA prior to liver transplantation (LT). Building on these insights, we developed the ZJU Criteria based on CNA fragments and tumor markers, a pre-LT risk prediction tool that integrates conventional clinical factors with cfDNA-derived CNA signatures, and validated it using internal and independent external cohorts.
Conclusion
Our findings suggest that post-transplant recurrence commonly originates from advanced subclones that emerge late during tumor evolution. The ZJU Criteria provides an accurate, non-invasive strategy that significantly improves pre-LT risk stratification and clinical decision-making for patients with HCC.
3.Application of single-cell RNA sequencing technology in Parkinson's disease
Ziyu LIU ; Dandan GENG ; Runjiao ZHANG ; Qing LIU ; Yibo LI ; Hongfang WANG ; Wenmeng XIE ; Wenyu WANG ; Jiaxin HAO ; Lei WANG
Chinese Journal of Tissue Engineering Research 2025;29(1):193-201
BACKGROUND:Parkinson's disease has the main pathological changes in the midbrain,especially in the dense substantia nigra,leading to impaired motor and non-motor function in patients.At present,research is limited by cellular heterogeneity,and its pathogenesis still needs to be further elucidated.In recent years,single-cell RNA sequencing(scRNA-seq)has gradually been applied in neurodegenerative diseases,which is of great significance for understanding intercellular heterogeneity,disease development mechanisms,and treatment strategies. OBJECTIVE:To review the research progress of scRNA-seq technology applied to Parkinson's disease in recent years,providing a theoretical basis for the application of scRNA-seq in the treatment and diagnosis of Parkinson's disease. METHODS:The first author used a computer system to search for relevant literature in the CNKI,WanFang,PubMed,and Web of Science databases,with the Chinese search terms"single-cell RNA sequencing,Parkinson's disease,cell heterogeneity,cell subtypes,dopaminergic neurons,glial cells"and English search terms"single-cell RNA seq,Parkinson disease,heterogenicity,subtypes,dopaminergic neurons,glial cells."71 articles were ultimately included for review and analysis. RESULTS AND CONCLUSION:(1)scRNA-seq is a high-throughput experimental technique that utilizes RNA sequencing at the single-cell level to quantify gene expression profiles in specific cell populations,revealing cellular mysteries at the molecular level.Compared with traditional sequencing techniques,scRNA-seq technology is used to reveal the diversity of cell types and changes in specific gene expression in complex tissues under various physiological and pathological conditions through automatic clustering analysis of cell transcriptome.(2)By using scRNA-seq,the development process of dopaminergic neurons and the unique functional characteristics of various cell subtypes are elucidated,in order to better understand potential therapeutic molecular targets.(3)The use of scRNA-seq analysis has improved our understanding of the response of Parkinson's disease glial cells,enabling us to comprehensively map and characterize different cell type populations,identify specific glial cell subpopulations related to neurodegeneration,and draw valuable single cell maps as reference data for future research.(4)The application of scRNA-seq to detect embryonic mice and stem cells will help improve the in vitro differentiation protocol and quality control of cell therapy,as well as evaluate the overall cell quality and developmental stage of dopaminergic neurons derived from stem cells.
4.Translation and validation of the communicative effectiveness index for the elderly
Xiaoqi XIE ; Dandan WANG ; Yulu YUAN ; Xuefeng LI ; FENFANG ; Han YANG ; Chengying JIANG
Modern Clinical Nursing 2025;24(3):24-31
Objective To translate the English version of communicative effectiveness index(CETI)into Chinese and validate its reliability and validity for use in the elderly population.Methods The English version of CETI was translated into Chinese and back-translated using the Brislin translation model.After adjustments and pilot testing,a Chinese version of CETI was created.Between January and March 2024,a total of 395 elderly individuals aged 60 years and over were recruited from Jiangsu and Henan Provinces via convenience sampling.A total of 30 elderly people were retested with the Chinese version of CETI after two weeks of primary test to assess the reliability and validity of the scale.Results The Chinese version of CETI comprised two dimensions:conversational comprehensibility(5 items)and conversational initiative(4 items).The Cronbach α coefficient of the scale was 0.831with the split-half reliability 0.785 and the test-retest reliability 0.909.The Cronbach α coefficients of each dimension ranged from 0.641 to 0.778.The test-retest reliability of each dimension ranged from 0.889 to 0.936.The KMO value of exploratory factor analysis was 0.893,Bartlett's sphericity test valueχ 2=583.291(P<0.01),and the total explanatory rate of variation was 63.305%.Conclusion The Chinese version of CETI has good reliability and validity.It is suitable to be used in the assessment of the status of verbal communicative function in the elderly.
5.Surveillance and early warning index system for schistosomiasis in the middle and lower reaches of the Yangtze River basin
Sanhong JIANG ; Yibiao ZHOU ; Shizhu LI ; Dandan LIN ; Qingwu JIANG ; Liyong WEN ; Shengming LI ; Fei HU ; Benjiao HU ; Jie ZHOU ; Chunli CAO ; Jing XU ; Jianwen XIE ; Changming WU ; Xiaolan YAN ; Weimin XU ; Jun GE ; Guanghui REN ; Xiaoli LIU
Chinese Journal of Endemiology 2025;44(4):259-264
Under the current situation of "low prevalence and low infection" of schistosomiasis in China, and to provide a basis for achieving the goal of eliminating schistosomiasis by 2030 proposed by the Healthy China Action (2019 - 2030) as scheduled, the Hunan Provincial Corps Hospital of the Chinese People's Armed Police Force established a schistosomiasis monitoring and early warning index system based on the previous studies on schistosomiasis early warning index system and the recent literature analysis, combined with the current potential risk factors affecting the transmission and prevalence of schistosomiasis, and organized two rounds of expert consultation and carried out project promotion meetings. The experts reached a consensus on the comprehensiveness and practicability of the index system, aiming to lay a solid foundation for construction of China's schistosomiasis prevention and control early warning system.
6.Clinical, genetic and transcriptomic characteristics of children with ACAN gene mutation
Xiaoyan WANG ; Haiying WU ; Rongrong XIE ; Linqi CHEN ; Xiuli CHEN ; Ting CHEN ; Hui SUN ; Dandan ZHANG ; Lili WANG ; Bingyu YANG ; Fengyun WANG
Chinese Journal of Applied Clinical Pediatrics 2025;40(11):847-851
Objective:To summarize the clinical and genetic characteristics of 23 children with pathogenic ACAN gene variants, enhance the understanding of this disorder, and explore possible regulatory mechanisms. Methods:A retrospective case series summary.The clinical characteristics and genetic analysis results of 23 children with ACAN gene variants treated in the Department of Endocrinology, Genetics and Metabolism, Children′s Hospital of Soochow University from January 2016 and September 2024 were analyzed retrospectively.Transcriptome sequencing was performed on peripheral blood samples from 3 of affected children and 3 age-matched healthy children as controls.Differentially expressed genes (DEGs) in the peripheral blood transcriptome profiles were identified.Gene ontology (GO) and Kyoto encyclopedia of genes and genomes (KEGG) pathway enrichment analyses were conducted to explore the potential signaling pathways involved. Results:Among the 23 cases, there were 13 males and 10 females, aged from 2 years and 8 months to 12 years old, with 11 cases presenting advanced bone age.Thirteen cases were treated with growth hormone (GH), including 6 cases who received concomitant gonadotropin-releasing hormone analogue therapy.The treatment duration ranged from 3 to 70 months, resulting in varying degrees of height improvement in all treated patients.Transcriptomic analysis identified 811 DEGs, with 516 up-regulated and 295 down-regulated.GO and KEGG enrichment analyses revealed that the heterozygous ACAN variants were significantly associated with FcγR-mediated phagocytosis, nuclear factor-κB signaling pathway, the intestinal immune network for IgA production, rheumatoid arthritis, and systemic lupus erythematosus signaling pathways. Conclusions:The predominant clinical manifestations of patients with ACAN gene variants are short stature and advanced bone age.Although GH provocation tests may indicate normal GH levels, GH therapy can be effective in improving height.Immune-related factors may play a role in the pathogenesis of this disorder.
7.Strategies for management of trauma orthopedic implant and effect on control of infections in operating rooms
Lin LIU ; Ying XU ; Lianen ZHANG ; Dandan NI ; Yun WANG ; Jing XIE ; Lanmei HE
Chinese Journal of Nosocomiology 2025;35(20):3168-3172
OBJECTIVE To explore the impact of trauma orthopedic implant management on the operating room in-fection control rate and the medical device vendor follow-up rate.METHODS Trauma orthopedic implant manage-ment was implemented at Shaoxing People's Hospital from Mar.2023 to Mar.2024,involving 2 047 trauma or-thopedic surgeries(study group).For comparison,a control group consisting of 2 067 trauma orthopedic surger-ies from Mar.2022 to Feb.2023 under routine management was selected.The impact of trauma orthopedic im-plant management on operating room efficiency,infection control rate and medical device vendor follow-up rate in both groups were analyzed.RESULTS The study group showed satisfaction rates of 78.65%and 91.35%for cir-culating cooperation familiarity and handwashing cooperation familiarity,respectively,both higher than those in the control group(P<0.001).The study group also demonstrated higher rates of standardized use of orthopedic trauma implants(96.43%),accurate item-code correspondence(98.19%)and timely availability(98.19%)than those in the control group,with a lower medical device vendor follow-up rate of 3.57%(P<0.001).The study group's monthly overtime hours,costs,time costs,average cost per re-disinfection and re-cleaning service and monthly re-disinfection re-cleaning frequency were 13.85 hours,235.86 yuan/day,25 233.51 yuan,0.35 yuan/time and 183.81 times/month,respectively,all lower than those in the control group(P<0.001).The study group had higher rates of consumable access compliance(99.22%),accurate charging(98.58%)and timely delivery(97.90%)than the control group(P<0.001).The study group also achieved a 100.00%implant regulatory recovery rate,higher than the control group(P<0.001).Furthermore,the surgical site infection rate in the study group was 1.91%,lower than that in the control group(P<0.001).CONCLUSIONS This study establishes a trauma orthopedic implant management system integrating supply chain management,an identification system and IoT technology.This model effectively addresses core issues such as the difficulty in regulating multiple vendors,blind spots in virtual warehousing and disorder in item-code tracing under the traditional vendor self-management model.It significantly improves operating room efficiency,reduces the surgical site infection rate,and achieves a notable decrease in the medical device vendor follow-up rate.
8.Analysis of the gene mutation of patients with congenital plasminogen deficiency
Dandan YU ; Yanhui JIN ; Haixiao XIE ; Feng LIANG ; Yifan LU ; Fei XU ; Mingshan WANG ; Lihong YANG
Chinese Journal of Laboratory Medicine 2025;48(12):1581-1585
Objective:To analyze the gene mutations of 18 patients with plasminogen (PLG) deficiency and to explore the clinical manifestations caused by PLG gene mutations.Methods:This study belongs to observational study-descriptive study: case series.Clinical data from 18 patients with PLG deficiency admitted to the First Affiliated Hospital of Wenzhou Medical University from January 1st, 2021 to May 31st, 2025 were collected. The age ranged from 16 to 70 years old, with an average of 48 years old. Among them, there were 10 males and 8 females. Anticoagulant blood samples were taken before treatment to measure and analyze plasminogen activity (PLG:A), plasminogen antigen (PLG:Ag), protein C activity, protein S activity, fibrinogen, antithrombin activity, D-dimer, and fibrin (fibrinogen) degradation products. PCR direct sequencing was used to analyze the 19 exons and flanking sequences of the PLG gene in these patients, and reverse sequencing was employed to verify the suspected mutations.Results:For the 18 patients, cranial MRI showed fresh cerebral infarction lesions, and PLG:A levels ranged from 19% to 67%, while no other lab indicators showed significant abnormalities, all presenting with dysplasminogenemia. Genetic analysis revealed five types of PLG gene mutations: c.1858G>A (p.Ala620Thr) heterozygous mutation, c.1858G>A (p.Ala620Thr) homozygous mutation, c.398A>G (p.His133Arg) heterozygous mutation, c.2108G>A (p.Gly703Asp) heterozygous mutation, and c.1702G>A (p.Gly568Arg) heterozygous mutation. Among the above, the c.1858G>A heterozygous mutation was the most common, and c.398A>G and c.1702G>A were identified for the first time.Conclusion:Patients with plasminogen deficiency caused by PLG gene defects are prone to occur cerebral infarction events, which may be related to impaired fibrinolytic function due to PLG gene mutations.
9.Analysis of the current situation and influencing factors of pain crisis in patients with advanced colorectal cancer
Tingyu XIE ; Shaolian TIAN ; Lu LUO ; Dandan SHU
China Modern Doctor 2025;63(30):34-37,72
Objective To investigate the current status of pain crisis in patients with advanced colorectal cancer(CRC)and analyze its influencing factors.Methods A total of 186 patients with advanced CRC who were hospitalized in the Oncology Department,the Second Affiliated Hospital of Guizhou University of Traditional Chinese Medicine from June 2024 to March 2025 were selected as the subjects of the investigation.General information questionnaires numerical rating scale,distress tolerance scale,self-rating anxiety scale,self-rating depression scale and quality of life assessment scales were used for the investigation.Logistic regression was used to analyze the influencing factors of pain crisis in patients with advanced CRC.Results Among the 186 CRC patients,87 experienced pain crises,with an incidence rate of 46.8%.The results indicated that pain type,use of analgesics,traditional Chinese medicine adjuvant therapy,metastasis radiotherapy and chemotherapy,pain intensity and pain tolerance were important influencing factors for pain crises in advanced CRC patients.Conclusion The incidence of pain crisis in patients with advanced CRC is relatively high.Nursing staff should promptly identify patients with pain crisis and implement targeted intervention strategies for high-risk patients to reduce the risk of pain crisis.
10.Clinical application of botulinum toxin A in adult tic disorders
Dandan XIE ; Yang LI ; Xinhua WAN
Chinese Journal of Neurology 2025;58(9):930-937
Objective:To investigate the efficacy of botulinum toxin type A (BTX-A) injections in treating motor tics in adult patients with tic disorders.Methods:A retrospective analysis was conducted on the baseline and clinical data of 25 adult tic disorder patients who received BTX-A treatment at the Movement Disorders Clinic of the Department of Neurology, Peking Union Medical College Hospital, from January 2019 to July 2023. Before the treatment, the Yale Global Tic Severity Scale (YGTSS) was used to assess the severity of motor and vocal tics. The injection sites and dosage of BTX-A were determined based on the distribution and severity of tic symptoms. Post-treatment improvement was evaluated via telephone follow-up.Results:Among the 25 patients, 18 were male and 7 were female, with an age of 27.0 (23.5, 31.0) years and a disease duration of 10.0 (5.5, 18.5) years. The pre-treatment YGTSS score was 41.3±12.3. After treatment, the time to onset of effect was 2.0 (1.0, 5.0) days, the peak efficacy was achieved at (15.5±9.4) days, and the duration of efficacy was 4.0 (2.5, 6.0) months. Post-treatment YGTSS score decreased to 14.7±11.3, with an improvement rate of 63.7%±24.9%. Significant efficacy was observed in 68.0% (17/25) of patients, 28% (7/25) showed moderate improvement, and 4% (1/25) had no response. Anxiety symptoms were alleviated in 91% (21/24) of patients, and premonitory urges were reduced in 90% (18/20) of patients. Retreatment in 13 patients with symptom recurrence remained effective. Adverse effects included facial stiffness in 4 patients, scalp tightness in 1, and mild neck muscle weakness in 5, all of which resolved spontaneously within 3-14 days; 16 patients reported no adverse effects.Conclusion:BTX-A is safe and effective in controlling motor tics in adult patients with tic disorders.

Result Analysis
Print
Save
E-mail